更新于：2024-12-06
Tianeptine Sodium
噻奈普汀钠
更新于：2024-12-06
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期- |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H25ClN2NaO4S |
InChIKeyUDFCCNYPCCUJOO-UHFFFAOYSA-N |
CAS号30123-17-2 |
关联
6
项与 噻奈普汀钠 相关的临床试验Evaluation of the Efficacy of Perioperative Administration of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery. A Double-Blinded Randomized Controlled Trial.
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19 With the Study of the Pathophysiology of the Phenomenon Using Positron Emission Tomography, Biochemical, Immunological and Electrophysiological Parameters.
Tianeptine for Treatment Resistant Depression
100 项与 噻奈普汀钠 相关的临床结果
登录后查看更多信息
100 项与 噻奈普汀钠 相关的转化医学
登录后查看更多信息
100 项与 噻奈普汀钠 相关的专利（医药）
登录后查看更多信息
32
项与 噻奈普汀钠 相关的文献（医药）2021-07-04The American journal of drug and alcohol abuse3区 · 医学
Tianeptine: a new frontier in surveillance and understanding through social media
3区 · 医学
Article
作者: Rushton, William ; Rivera, Jessica
Interest in the abuse of tianeptine in the United States has been increasing over the past decade (1). The xenobiotic, which is known under the trade name internationally as Stablon or Coaxil, was ...
2018-11-01Psychosomatics4区 · 医学
Tianeptine Abuse and Dependence: Case Report and Literature Review
4区 · 医学
Review
作者: Alan Hsu ; Al Alam ; Kristin Beizai ; Rahul Lauhan
BACKGROUND:
Tianeptine (Stablon, Coaxil) abuse and dependence has become increasingly prominent worldwide with recent presence in the United States.
OBJECTIVE:
In this article, we add a case to the growing literature on tianeptine dependence, the first of which is concerning for the presence of an adulterant, and present a comprehensive literature review.
METHODS:
A literature search was conducted on July 2, 2018 on PubMed for articles using the keywords "tianeptine abuse" and "tianeptine dependence."
RESULTS:
Literature search resulted in 25 articles and encompassed 65 patients. A majority of patients were male and age ranged from 19 to 67. Routes of intake included oral, intravenous, and insufflation. In the 15 cases of overdose, 8 combined ingestion with at least one other substance, of which 3 resulted in death. Six additional deaths are reported involving tianeptine (9 total).
CONCLUSION:
Tianeptine abuse and dependence has become a cause for concern in approved markets with recent emergence in the United States. Psychiatrists should be aware of a potentially fatal opiate-like withdrawal in the absence of positive urine drug screens or cases where withdrawal does not follow expected patterns. Tianeptine users should be educated regarding risk associated with this drug. Without further intervention, additional cases should be anticipated.
2014-09-01International journal of clinical pharmacology and therapeutics4区 · 医学
Pharmacokinetic and bioequivalence assessment of two formulations of tianeptine sodium in healthy male volunteers
4区 · 医学
Article
作者: Kim, Bo-Hyung ; Zheng, Renhua
BACKGROUND:
Tianeptine is widely used for controlling depressive symptoms.
OBJECTIVE:
The aim of this study was to evaluate the bioequivalence between the generic (test) formulation containing tianeptine sodium 12.5 mg and the branded (reference) formulation Stablon® with regard to their pharmacokinetic profiles.
METHODS:
A randomized, two-sequence, two-treatment crossover study was conducted in healthy male Korean volunteers. All of the enrolled subjects were allocated to one of two sequence groups. They were administered a tablet of the test or reference formulation and then administered the alternative formulation after a 7-day washout period. The blood samples were taken before dosing and at 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and 10 hours after dosing. The plasma concentrations of tianeptine were analyzed using high-performance liquid chromatography with tandem mass spectrometer. Tolerability was assessed throughout the study.
RESULTS:
The pharmacokinetic parameters were assessed in the 40 subjects who completed the study. The tianeptine C(max) for the test formulation was 283.13 ± 57.58 ng/mL (mean ± SD) and that for the reference formulation was 272.50 ± 59.00 ng/mL. The AUC(last) of tianeptine was 803.24 ± 180.94 ng×h/mL for the test formulation and 792.27 ± 180.93 ng×h/mL for the reference formulation. The geometric mean ratio (%) of the test to reference formulation was 104.04 (90% CI, 99.66 - 108.61) for C(max) and 101.30 (98.01 - 104.71) for AUC(last). Clinically significant adverse events were not reported during the study.
CONCLUSION:
The test and reference formulations of tianeptine were bioequivalent with regard to the pharmacokinetic parameters of Cmax and AUC(last). Both formulations were tolerated by all of the participants.
100 项与 噻奈普汀钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 中国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (RT) | 築廠繭鏇觸廠構廠壓齋(積蓋壓餘廠遞觸淵蓋築): P-Value = 120 days 更多 | - | 2018-11-01 | |
Tianeptine + RT | |||||||
N/A | - | 鹹獵醖糧構範壓選艱襯(選齋衊壓壓範遞糧蓋網) = 壓蓋繭壓衊壓繭網鬱鹽 鹹鹽構憲鑰繭窪夢淵壓 (衊餘製蓋範選艱鑰鹽襯 ) 更多 | - | 2007-11-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用